scholarly journals Antiviral Agents for the Prevention and Treatment of Herpes Simplex Virus Type-1 Infection in Clinical Oncology: A Network Meta-Analysis

2020 ◽  
Vol 17 (23) ◽  
pp. 8891
Author(s):  
Farah Wasim Aribi Al-Zoobaee ◽  
Loo Yee Shen ◽  
Sajesh K. Veettil ◽  
Divya Gopinath ◽  
Mari Kannan Maharajan ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Viral Infections ◽  
Meta Analysis ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Assessment Development ◽  
Simplex Virus

Cancer therapy may be complicated and compromised by viral infections, including oral herpes simplex virus (HSV) infection. This network meta-analysis aimed to identify the best antiviral agent to prevent or treat oral HSV infection in patients being treated for cancer. A search was conducted for trials published since inception until the 10th of May 2020 in MEDLINE, EMBASE and the Cochrane Central Register of Controlled Trials. A network meta-analysis was performed on the data from randomized controlled trials that assessed antiviral agents for preventive or therapeutic activity vs. placebo, no treatment or any other active intervention in patients being treated for cancer. The agents were ranked according to their effectiveness in the prevention of oral HSV using surface under the cumulative ranking (SUCRA). Grading of Recommendations, Assessment, Development and Evaluations (GRADE) was used to assess the certainty of the evidence. In total, 16 articles were included. The pooled relative risk (RR) to develop oral HSV infection in the acyclovir group was 0.17 (95% CI: 0.10, 0.30), compared to 0.22 (95% CI: 0.06, 0.77) in the valacyclovir group. Acyclovir ranked highest for the prevention of oral HSV followed by valacyclovir. Subgroup analysis with different acyclovir regimens revealed that the best regimens in terms of HSV-1 prevention were 750 mg/m2 acyclovir administered intravenously followed by 1600 mg per day orally. Acyclovir (250 mg/m2 per day) administered intravenously was the least effective against the prevention of oral HSV.

scholarly journals Surveillance for Antiviral-Agent-Resistant Herpes Simplex Virus in the General Population with Recurrent Herpes Labialis

2002 ◽  
Vol 46 (9) ◽  
pp. 3042-3044 ◽  
Author(s):  
Teresa H. Bacon ◽  
Ron J. Boon ◽  
Margaret Schultz ◽  
Cheryl Hodges-Savola
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
General Population ◽  
Population Survey ◽  
Antiviral Agents ◽  
Antiviral Agent ◽  
The United States ◽  
Herpes Labialis ◽  
Recurrent Herpes ◽  
Simplex Virus

ABSTRACT In a general population survey in the United States, the prevalence of antiviral-agent-resistant herpes simplex virus was very low among more than 1,000 isolates from individuals with an episode of recurrent herpes labialis not treated with topical antiviral agents. Two isolates had borderline resistance to acyclovir (0.2%), and all were susceptible to penciclovir.

scholarly journals Immune Response to Herpes Simplex Virus Infection and Vaccine Development

Vaccines ◽  
2020 ◽  
Vol 8 (2) ◽  
pp. 302 ◽  
Author(s):  
Anthony C. Ike ◽  
Chisom J. Onu ◽  
Chukwuebuka M. Ononugbo ◽  
Eleazar E. Reward ◽  
Sophia O. Muo
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Viral Infections ◽  
Recombinant Dna ◽  
Vaccine Development ◽  
The Body ◽  
Effective Vaccine ◽  
Subunit Vaccines ◽  
Simplex Virus ◽  
Hsv Infections

Herpes simplex virus (HSV) infections are among the most common viral infections and usually last for a lifetime. The virus can potentially be controlled with vaccines since humans are the only known host. However, despite the development and trial of many vaccines, this has not yet been possible. This is normally attributed to the high latency potential of the virus. Numerous immune cells, particularly the natural killer cells and interferon gamma and pathways that are used by the body to fight HSV infections have been identified. On the other hand, the virus has developed different mechanisms, including using different microRNAs to inhibit apoptosis and autophagy to avoid clearance and aid latency induction. Both traditional and new methods of vaccine development, including the use of live attenuated vaccines, replication incompetent vaccines, subunit vaccines and recombinant DNA vaccines are now being employed to develop an effective vaccine against the virus. We conclude that this review has contributed to a better understanding of the interplay between the immune system and the virus, which is necessary for the development of an effective vaccine against HSV.

scholarly journals Cytopathic effect inhibition assay for determining the in-vitro susceptibility of herpes simplex virus to antiviral agents

1999 ◽  
Vol 44 (5) ◽  
pp. 705-708 ◽  
Author(s):  
Manuel Cotarelo ◽  
Pilar Catalán ◽  
Carlos Sánchez-Carrillo ◽  
Ana Menasalvas ◽  
Emilia Cercenado ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Cytopathic Effect ◽  
Antiviral Agents ◽  
Inhibition Assay ◽  
In Vitro Susceptibility ◽  
Simplex Virus

scholarly journals Resveratrol as a Novel Anti-Herpes Simplex Virus Nutraceutical Agent: An Overview

Viruses ◽  
2018 ◽  
Vol 10 (9) ◽  
pp. 473 ◽  
Author(s):  
Giuseppe Annunziata ◽  
Maria Maisto ◽  
Connie Schisano ◽  
Roberto Ciampaglia ◽  
Viviana Narciso ◽  
...  
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Bioactive Compounds ◽  
Antiviral Agents ◽  
Mechanisms Of Action ◽  
The Body ◽  
Human Virus ◽  
Simplex Virus ◽  
Different Parts ◽  
Hsv Infections

The herpes simplex virus (HSV) is a common human virus affecting many people worldwide. HSV infections manifest with lesions that occur in different parts of the body, including oral, ocular, nasal, and genital skin and mucosa. In rare cases, HSV infections can be serious and lethal. Several anti-HSV drugs have been developed, but the existence of mutant viruses resistant to these drugs led to the individuation of novel antiviral agents. Plant-derived bioactive compounds, and more specifically polyphenols, have been demonstrated to exert marked anti-HSV activity and, among these, resveratrol (RSV) would be considered a good candidate. The purpose of this manuscript is to review the available literature elucidating the efficacy of RSV against HSV and the main demonstrated mechanisms of action.

Viral Infections in Pregnancy – Part 1: CMV, Ebola Virus, Viral Hepatitis, HSV, and HIV

2019 ◽  
Author(s):  
Patrick Duff
Keyword(s):  
Herpes Simplex Virus ◽  
Herpes Simplex ◽  
Viral Hepatitis ◽  
Ebola Virus ◽  
Viral Infections ◽  
Perinatal Period ◽  
Hiv Management ◽  
Simplex Virus ◽  
Viral Etiologies ◽  
In Pregnancy

A number of viral etiologies contribute to morbidity and mortality in pregnancy and the perinatal period. Here we discuss some of the major viral infections that occur in pregnancy. This review focuses on infections of cytomegalovirus (CMV), viral hepatitis, herpes simplex virus (HSV), and human immunodeficiency virus (HIV); other viral etiologies are discussed in part 2 of this topic. It is imperative to understand the risks, clinical course, diagnostic methodology, and management of these illnesses. This review contains 1 figure, 8 tables, and 67 references. Keywords: viral infection, pregnancy, prenatal, perinatal, cytomegalovirus, Ebola virus, viral hepatitis, herpes simplex virus, HIV, management

Sign in / Sign up

Export Citation Format

Share Document